Laman UtamaLAURUSLABS • NSE
Laurus Labs Ltd
₹467.00
27 Sep, 4:00:40 PTG GMT+5:30 · INR · NSE · Penafian
SahamSekuriti tersenarai IN
Tutup sebelumnya
₹463.20
Julat hari
₹459.05 - ₹472.90
Julat tahun
₹349.40 - ₹518.00
Permodalan pasaran
252.00B INR
Bilangan Purata
2.45J
Nisbah P/E
170.26
Hasil dividen
0.17%
Pertukaran utama
NSE
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(INR)Jun 2024Perubahan T/T
Hasil
11.95B1.11%
Perbelanjaan pengendalian
5.90B13.96%
Pendapatan bersih
125.10J-49.66%
Margin untung bersih
1.05-50.00%
Pendapatan bagi setiap syer
0.23-50.00%
EBITDA
1.60B1.31%
Kadar cukai berkesan
33.02%—
Jumlah aset
Jumlah liabiliti
(INR)Jun 2024Perubahan T/T
Pelaburan tunai dan jangka pendek
1.42B192.30%
Jumlah aset
——
Jumlah liabiliti
——
Jumlah ekuiti
41.16B—
Syer tertunggak
543.91J—
Harga kepada buku
6.07—
Pulangan pada aset
——
Pulangan pada modal
2.53%—
Perubahan bersih dalam tunai
(INR)Jun 2024Perubahan T/T
Pendapatan bersih
125.10J-49.66%
Tunai daripada operasi
——
Tunai daripada pelaburan
——
Tunai daripada pembiayaan
——
Perubahan bersih dalam tunai
——
Aliran tunai bebas
——
Perihal
Laurus Labs is an Indian multinational pharmaceutical and biotechnology company headquartered in Hyderabad. Its focus areas include active pharmaceutical ingredients, generic formulations, custom synthesis, biotechnology, veterinary APIs and agrochemicals. The company was founded in 2005 by Satyanarayana Chava. Laurus Labs has its eight manufacturing plants located at Visakhapatnam, Hyderabad and Bangalore. The manufacturing units have received one or more approvals from USFDA, WHO, NIP Hungary, KFDA, MHRA, TGA, and PMDA. The company operates through its subsidiaries in Europe and United States and also offers its services in contract research, clinical research and analytical research through its R&D centers. The R&D centres are based in Hyderabad, Visakhapatnam and United States. Wikipedia
Diasaskan
2005
Pekerja
6,007
Cari
Kosongkan carian
Tutup carian
Apl Google
Menu utama